NCT01093326View on ClinicalTrials.gov

Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL

Enrollment

353

Participants

Timeline

Start Date

May 12, 2010

Primary Completion Date

September 6, 2023

Study Completion Date

September 6, 2023

Conditions

Multiple Sclerosis

Interventions

DRUG

Ponesimod 10 mg

Ponesimod 10 mg oral use

DRUG

Ponesimod 20 mg

Ponesimod 20 mg oral use

DRUG

Ponesimod 40 mg

Ponesimod 40 mg oral use

Trial Locations (71)

Unknown

Phoenix

Scottsdale

Palo Alto

Sacramento

Venice

Indianapolis

Kansas City

Lenexa

Latham

Schenectady

Stony Brook

Raleigh

Cincinnati

Columbus

Burlington

Kirkland

Vienna

Sofia

Ottawa

Brno

Jihlava

Olomouc

Ostrava-Poruba

Prague

Teplice

Helsinki

Hyvinkää

Tampere

Turku

Montpellier

Berlin

Essen

Ulm

Budapest

Esztergom

Győr

Miskolc

Tel Litwinsky

Ẕerifin

Breda

Katowice

Poznan

Warsaw

Wroclaw

Cluj-Napoca

Timișoara

Kazan'

Moscow

Nizhny Novgorod

Pyatigorsk

Saint Petersburg

Samara

Saratov

Ufa

Belgrade

Kragujevac

Niš

Majadahonda

Málaga

Seville

Gothenburg

Stockholm

Umeå

Lugano

Chernihiv

Dnipropetrovsk

Kyiv

Odesa

Bristol

London

Plymouth

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Actelion

INDUSTRY

NCT01093326 - Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis | Biotech Hunter | Biotech Hunter